JI-101

• Description :

  JI-101 is an orally available multi-kinase inhibitor of VEGFR2, PDGFRβ and EphB4 with potent anti-cancer activity.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Ephrin Receptor; PDGFR; VEGFR

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cardiovascular Disease; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/JI-101.html

• Purity :

  99.78

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=C(NC1=CC(Br)=CC=C1OC)NC2=CC=CC3=C2C=CN3CC4=CC(N)=NC=C4

• Molecular Formula :

  C22H20BrN5O2

• Molecular Weight :

  466.33

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Gurav SD, et al. Pharmacokinetics, tissue distribution and identification of putative metabolites of JI-101 - a novel triple kinase inhibitor in rats. Arzneimittelforschung. 2012 Jan;62 (1) :27-34.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  PDGFRβ; VEGFR2/KDR/Flk-1

• CAS Number :

  [900573-88-8]